Previous close | 2.8200 |
Open | 2.7700 |
Bid | 2.7600 x 734600 |
Ask | 2.7800 x 258500 |
Day's range | 2.6650 - 2.7800 |
52-week range | 1.2800 - 3.2300 |
Volume | |
Avg. volume | 274,931 |
Market cap | 348.927M |
Beta (5Y monthly) | 1.03 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.3010 |
Earnings date | 29 Apr 2020 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 2.96 |
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
Avita Medical Inc. (RCEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
VALENCIA, Calif. and MELBOURNE, Australia, Jan. 19, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical” or the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today changes to its management structure designed to advance its strategic growth plans and accelerate execution under recently appointed Chief Executive Officer, James Co